Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
- Category: DNA RNA and Cells
- Published on Thursday, 23 February 2017 19:40
- Hits: 1104
EXTON, PA, USA I February 23, 2017 I Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the first patient has been dosed in the Phase I portion of the Phase I/II clinical trial of FCX-007, the Company’s gene therapy candidate for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)—a devastating, progressive genetic skin disease with a high mortality rate.
“Dosing the first patient in the clinical setting with this potentially transformative approach for the treatment of RDEB is an exciting milestone in the development of FCX-007,” said John Maslowski, Chief Executive Officer of Fibrocell. “We are grateful to our staff, the teams at Intrexon Corporation and Stanford University School of Medicine, and the patient advocacy groups whose tireless efforts have enabled us to attain this goal. With no FDA-approved therapies, we believe FCX-007 has the promise to be a significant advance in the care of RDEB patients.”
“Fibrocell’s approach to treatment of RDEB is distinctive,” said Alfred Lane, MD, Professor of Dermatology and Pediatrics (Emeritus) at Stanford University School of Medicine, and Chief Medical Advisor of Fibrocell. “By genetically modifying autologous fibroblasts to produce functional type VII collagen—a protein that forms anchoring fibrils responsible for binding the layers of skin—FCX-007 targets the underlying cause of RDEB and offers the potential to bring relief to patients suffering from the debilitating, painful blisters and wounds of the disease.”
Six adult patients are targeted for the Phase I portion of the trial. Additional patients are expected to be dosed after a required four-week wait period and subsequent health assessment. Twelve-week post-treatment data for safety, mechanism of action and efficacy for multiple patients in the Phase I portion of this trial are expected in the third quarter of 2017.
FCX-007 has been granted Orphan Drug, Pediatric Rare Disease and Fast Track Designation by the U.S. Food and Drug Administration. Fibrocell is developing FCX-007 in collaboration with Intrexon Corporation (XON), a leader in synthetic biology
About the Phase I/II Clinical Trial
The primary objective of this open-label clinical trial is to evaluate the safety of FCX-007 in RDEB patients. Additionally, the trial will assess the mechanism of action of FCX-007 through evaluation of type VII collagen (COL7), expression and the presence of anchoring fibrils, as well as the efficacy of FCX-007 through evidence of wound healing. Assessments are performed at 4-, 12-, 25- and 52-weeks post-administration of FCX-007. Six adult patients are expected to be treated with FCX-007 in the Phase I portion of the trial and six pediatric patients in the Phase II portion of the trial. Prior to conducting clinical trials on pediatric patients, Fibrocell is required to obtain allowance from the U.S. Food and Drug Administration (FDA) by submitting evidence of FCX-007 activity in adult patients and data from its completed pre-clinical toxicology study. To learn more about the FCX-007 Phase I/II clinical trial, please visit www.clinicaltrials.gov and search the identifier NCT02810951.
FCX-007 is Fibrocell's clinical-stage, gene therapy product candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a congenital and progressive orphan skin disease caused by the deficiency of the protein type VII collagen (COL7). FCX-007 is a genetically-modified autologous fibroblast that encodes the gene for COL7 and is being developed in collaboration with Intrexon Corporation. By genetically modifying autologous fibroblasts ex vivo to produce COL7, culturing them and then treating wounds locally via injection, FCX-007 offers the potential to address the underlying cause of the disease by providing high levels of COL7 directly to the affected areas while avoiding systemic distribution.
About Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Recessive dystrophic epidermolysis bullosa (RDEB) is the most severe form of dystrophic epidermolysis bullosa (DEB), a congenital, progressive, devastatingly painful and debilitating genetic disorder that often leads to death. RDEB is caused by a mutation of the COL7A1 gene, the gene which encodes for type VII collagen, a protein that forms anchoring fibrils. Anchoring fibrils hold together the layers of skin, and without them, skin layers separate causing severe blistering, open wounds and scarring in response to friction, including normal daily activities like rubbing or scratching. Children who inherit the condition are often called "butterfly children" because their skin is as fragile as a butterfly's wings. We estimate there are approximately 1,100 – 2,500 RDEB patients in the U.S. Currently, treatments for RDEB address only the sequelae, including daily bandaging, hydrogel dressings, antibiotics, feeding tubes and surgeries.
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, has begun a Phase I/II trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of linear scleroderma. In addition, Fibrocell has a third program in the research phase for the treatment of arthritis and related conditions. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (XON), a leader in synthetic biology.